tiprankstipranks
Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes
Company Announcements

Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes

Don't Miss our Black Friday Offers:

An update from Replimune Group (REPL) is now available.

Replimune Group, Inc. has released promising results from their IGNYTE clinical trial, showing that one-third of melanoma patients who had not responded to prior anti-PD1 therapy saw improvement when treated with a combination of RP1 and nivolumab. These findings revealed durable responses exceeding six months and tolerable side effects, primarily of mild grade. The comprehensive data is set to be presented at an upcoming medical congress, highlighting the treatment’s potential in improving outcomes for melanoma patients previously unresponsive to standard therapies.

Find detailed analytics on REPL stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAmazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
TheFlyReplimune price target raised to $18 from $14 at BMO Capital
TheFlyClosing Bell Movers: Gap jumps 15% after Q3 earnings beat, guidance raise
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App